ReShape Announces Positive Preclinical Results for Diabetes Neuromodulation Device

ReShape Lifesciences announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints. The study was conducted as a part of the National Institutes of Health (NIH) Small Business Innovation Research Phase I grant that was previously awarded August 1, 2019.

The preclinical investigation consisted of simultaneous electrical blockade and stimulation of individual vagal nerve branches and was conducted in a type 2 diabetic porcine animal model. Results showed a significant reduction of blood glucose. Histopathology of organ systems effected by the neuromodulation demonstrated healthy tissue.

"Bioelectronic medicine represents a growing and exciting field as it supports the potential for less dependence on drug therapy and addresses the challenges associated with daily compliance for those suffering from diabetes," said Bart Bandy, President & CEO of ReShape Lifesciences Inc. "Our exploration of neuromodulation for diabetes aligns with the ReShape Lifesciences™ corporate strategy to build our portfolio and pipeline with technologies and services that improve the treatment of obesity and metabolic diseases. Based on these positive outcomes, the preclinical study represents a successful completion of the NIH Phase I grant and we look forward to advancing this unique diabetes focused innovation."

"The ReShape Lifesciences Diabetes Bloc-Stim Neuromodulation technology has accomplished key goals through the NIH Phase I Small Business Innovation Research grant study. The preliminary data strongly calls for pursuit of further evaluating this treatment for type 2 diabetes mellitus," said Charles Billington, M.D., Chief of Endocrinology at the VA Medical Center in Minneapolis, MN and Professor of Medicine at the University of Minnesota, and the lead advisor in the ReShape Lifesciences preclinical diabetes research program.